To explore the role of SNF2L in cancer development, we employed CRISPR/Cas9 technology to generate SNF2L-deficient MDA-MB-231 breast cancer cells, as confirmed by western blotting (Fig. 1A, uncropped original western blots Fig. 1A). This evidence concerns the gene SMARCA1 and cancer.